KR20080079702A - 위장관 염증 질환의 치료에서 ｃｄ25 결합 분자의 용도 - Google Patents

위장관 염증 질환의 치료에서 ｃｄ25 결합 분자의 용도 Download PDF

Info

Publication number
KR20080079702A
KR20080079702A KR1020087020504A KR20087020504A KR20080079702A KR 20080079702 A KR20080079702 A KR 20080079702A KR 1020087020504 A KR1020087020504 A KR 1020087020504A KR 20087020504 A KR20087020504 A KR 20087020504A KR 20080079702 A KR20080079702 A KR 20080079702A
Authority
KR
South Korea
Prior art keywords
tyr
ser
gly
amino acid
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020087020504A
Other languages
English (en)
Korean (ko)
Inventor
한스요에르그 아담
로타르 파르베르
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20080079702A publication Critical patent/KR20080079702A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020087020504A 2000-03-30 2001-03-28 위장관 염증 질환의 치료에서 ｃｄ25 결합 분자의 용도 Ceased KR20080079702A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0007911.1 2000-03-30
GBGB0007911.1A GB0007911D0 (en) 2000-03-30 2000-03-30 Organic compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020027009850A Division KR20020084107A (ko) 2000-03-30 2001-03-28 위장관 염증 질환의 치료에서 ｃｄ25 결합 분자의 용도

Publications (1)

Publication Number Publication Date
KR20080079702A true KR20080079702A (ko) 2008-09-01

Family

ID=9888901

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020087020504A Ceased KR20080079702A (ko) 2000-03-30 2001-03-28 위장관 염증 질환의 치료에서 ｃｄ25 결합 분자의 용도
KR1020027009850A Ceased KR20020084107A (ko) 2000-03-30 2001-03-28 위장관 염증 질환의 치료에서 ｃｄ25 결합 분자의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020027009850A Ceased KR20020084107A (ko) 2000-03-30 2001-03-28 위장관 염증 질환의 치료에서 ｃｄ25 결합 분자의 용도

Country Status (18)

Country Link
US (2) US20050226872A1 (https=)
EP (1) EP1268553A1 (https=)
JP (1) JP2003528890A (https=)
KR (2) KR20080079702A (https=)
CN (1) CN1416432A (https=)
AU (2) AU4651601A (https=)
BR (1) BR0109549A (https=)
CA (1) CA2401249A1 (https=)
GB (1) GB0007911D0 (https=)
HU (1) HUP0301846A3 (https=)
IL (1) IL151089A0 (https=)
NO (1) NO20024579L (https=)
NZ (1) NZ520547A (https=)
PL (1) PL357014A1 (https=)
RU (1) RU2286797C2 (https=)
SK (1) SK13892002A3 (https=)
WO (1) WO2001072845A1 (https=)
ZA (1) ZA200207736B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170056713A (ko) * 2011-05-02 2017-05-23 밀레니엄 파머슈티컬스 인코퍼레이티드 항-α4β7 항체에 대한 제형

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2443405A1 (en) * 2001-04-06 2002-10-17 University Of Bristol Use of cd25 binding molecules in steroid-resistant patients
EP2235536A4 (en) * 2007-12-20 2011-05-04 Lab Corp America Holdings HER-2-DIAGNOSTIC PROCEDURE
ES2637411T3 (es) 2008-12-01 2017-10-13 Laboratory Corporation Of America Holdings Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95
EP2387711B1 (en) * 2009-01-15 2015-04-22 Laboratory Corporation of America Holdings Methods of determining patient response by measurement of her-3
JP2012515353A (ja) * 2009-01-15 2012-07-05 ラボラトリー コーポレイション オブ アメリカ ホールディングス Ｈｅｒ−２発現の測定による患者の反応を判定する方法
RU2500427C2 (ru) * 2010-07-15 2013-12-10 Олег Ильич Эпштейн Лекарственное средство для лечения функциональных нарушений желудочно-кишечного тракта и способ лечения функциональных нарушений желудочно-кишечного тракта
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018183929A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT60768A (en) * 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
DE69937057T2 (de) * 1998-07-27 2008-05-29 Novartis Ag Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170056713A (ko) * 2011-05-02 2017-05-23 밀레니엄 파머슈티컬스 인코퍼레이티드 항-α4β7 항체에 대한 제형
KR101875155B1 (ko) * 2011-05-02 2018-07-09 밀레니엄 파머슈티컬스 인코퍼레이티드 항-α4β7 항체에 대한 제형
KR20180080354A (ko) * 2011-05-02 2018-07-11 밀레니엄 파머슈티컬스 인코퍼레이티드 항-α4β7 항체에 대한 제형

Also Published As

Publication number Publication date
HUP0301846A2 (hu) 2003-09-29
BR0109549A (pt) 2003-06-10
KR20020084107A (ko) 2002-11-04
AU2001246516B2 (en) 2005-06-30
CA2401249A1 (en) 2001-10-04
NZ520547A (en) 2005-04-29
PL357014A1 (en) 2004-07-12
ZA200207736B (en) 2003-05-08
NO20024579L (no) 2002-11-11
SK13892002A3 (sk) 2003-05-02
IL151089A0 (en) 2003-04-10
CN1416432A (zh) 2003-05-07
US20050226872A1 (en) 2005-10-13
RU2002127800A (ru) 2004-03-27
US20090041775A1 (en) 2009-02-12
GB0007911D0 (en) 2000-05-17
JP2003528890A (ja) 2003-09-30
RU2286797C2 (ru) 2006-11-10
WO2001072845A1 (en) 2001-10-04
NO20024579D0 (no) 2002-09-24
HUP0301846A3 (en) 2010-07-28
EP1268553A1 (en) 2003-01-02
AU4651601A (en) 2001-10-08

Similar Documents

Publication Publication Date Title
US20090041775A1 (en) Use of CD25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract
JP7575102B2 (ja) Ｍｕｃ１８に特異的な抗体
CN109963592B (zh) Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途
TW200815468A (en) Use of organic compounds
NZ544410A (en) Anti-ngf antibodies for the treatment of various disorders
CN104402999A (zh) Trail受体结合剂和其用途
JP2018512435A (ja) Ｇｄｆ８阻害剤を用いて、強度及び機能を増加させる方法
EA006314B1 (ru) Способ ингибирования прогрессивного развития или стабилизации волчаночного нефрита
JP7578289B2 (ja) Ｍｕｃ１８に特異的な抗体
WO2019051164A1 (en) ANTIBODIES AGAINST PROTEIN 1 OF PROGRAMMED CELL DEATH
RS65652B1 (sr) Postupci lečenja bolesti u kojima je dejstvo il-13 štetno pomoću antitela protiv il-13
HK1213782A1 (zh) 在诊断和治疗类风湿性关节炎中使用的包含抗-cd6单克隆抗体的药物组合物
CN115551886A (zh) 用于ttr淀粉样变性的联合疗法
AU2001246516A1 (en) Use of CD25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract
US20220111008A1 (en) Use of il-15 protein complex joint pd-l1 antibody for treating tumor diseases
JP2003528890A5 (https=)
AU2008265974A1 (en) Use of TACI-Ig fusion protein such as atacicept for the manufacture of a medicament for treating lupus erythematosus
DE69630682T2 (de) Synthetische peptide und diese enthaltende arzneimittel zur behandlung des systemischen lupus erythematodes
JP2026504943A (ja) 併用療法のための方法および組成物
KR20250090398A (ko) 백혈구 면역글로불린 유사 수용체 하위 패밀리 b 구성원 2(lilrb2)에 결합하는 항체 및 그 용도
JP3973360B2 (ja) 関節リウマチまたは皮膚疾患の処置に使用するためのｃｄ２５結合分子
CN112439060B (zh) Pd-l1免疫疗法的新用途
KR20240004761A (ko) 항-baffr 항체를 사용한 전신 홍반성 루푸스의 치료
EA040534B1 (ru) Способы увеличения безжировой массы тела с помощью антитела к gdf8 или его антигенсвязывающего фрагмента и тренировок с сопротивлением

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20080821

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20090105

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20100226

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20090105

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I